Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
FITC Phalloidin (HB0814)
Description:Green fluorescent cytoskeleton stain. Binds and labels F-actin.
Piperafizine B (HB4029)
Description:Analog of Piperafizine A. Potentiator of vincristine cytotoxicity.
Purity:>98%
Thiazovivin (HB3240)
Description:Rock inhibitor. Improves hESCs survival and fibroblast reprogramming efficiency and iPSCs induction.
Purity:>97%
Anti-Vimentin antibody ValidAbâ„¢ (HB6497)
Description:Monoclonal antibody to Vimentin - class III intermediate filament expressed in mesenchymal cells used as a marker of epithelial-mesenchymal transition. Part of the ValidAbâ„¢ range of highly validated, data-rich antibodies.Â
Host: MouseClonality: MonoclonalReactivity Tested: Rat, Human, Mouse (no staining)